Apomorphine Hydrochloride

Apomorphine Hydrochloride · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 3, 2028

~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (60)

Apr 19, 2036method-of-use (U-2825)US 10449146
Apr 19, 2036method-of-use (U-2825)US 10449146
Apr 19, 2036method-of-use (U-2825)US 10449146
Apr 19, 2036method-of-use (U-2825)US 10449146
Apr 19, 2036method-of-use (U-2825)US 10449146
Apr 19, 2036method-of-use (U-2825)US 10959943
Apr 19, 2036method-of-use (U-2825)US 10959943
Apr 19, 2036method-of-use (U-2825)US 10959943
Apr 19, 2036method-of-use (U-2825)US 10959943
Apr 19, 2036method-of-use (U-2825)US 10959943
Dec 16, 2031formulationUS 11419769
Dec 16, 2031formulationUS 11419769
Dec 16, 2031formulationUS 11419769
Dec 16, 2031formulationUS 11419769
Dec 16, 2031formulationUS 11419769
Dec 16, 2031formulationUS 8414922
Dec 16, 2031formulationUS 8414922
Dec 16, 2031formulationUS 8414922
Dec 16, 2031formulationUS 8414922
Dec 16, 2031formulationUS 8414922
Dec 16, 2031formulationUS 8846074
Dec 16, 2031formulationUS 8846074
Dec 16, 2031formulationUS 8846074
Dec 16, 2031formulationUS 8846074
Dec 16, 2031formulationUS 8846074
Jun 11, 2030formulationUS 104207633.9y
Jun 11, 2030formulationUS 104207633.9y
Jun 11, 2030formulationUS 104207633.9y
Jun 11, 2030formulationUS 104207633.9y
Jun 11, 2030formulationUS 104207633.9y
Jun 11, 2030formulationUS 90444753.9y
Jun 11, 2030formulationUS 90444753.9y
Jun 11, 2030formulationUS 90444753.9y
Jun 11, 2030formulationUS 90444753.9y
Jun 11, 2030formulationUS 90444753.9y
Jun 11, 2030formulationUS 92832193.9y
Jun 11, 2030formulationUS 92832193.9y
Jun 11, 2030formulationUS 92832193.9y
Jun 11, 2030formulationUS 92832193.9y
Jun 11, 2030formulationUS 92832193.9y
Jun 11, 2030method-of-use (U-2825)US 93269813.9y
Jun 11, 2030method-of-use (U-2825)US 93269813.9y
Jun 11, 2030method-of-use (U-2825)US 93269813.9y
Jun 11, 2030method-of-use (U-2825)US 93269813.9y
Jun 11, 2030method-of-use (U-2825)US 93269813.9y
Jun 11, 2030formulationUS 96690193.9y
Jun 11, 2030formulationUS 96690193.9y
Jun 11, 2030formulationUS 96690193.9y
Jun 11, 2030formulationUS 96690193.9y
Jun 11, 2030formulationUS 96690193.9y
Jun 11, 2030method-of-use (U-2825)US 96690213.9y
Jun 11, 2030method-of-use (U-2825)US 96690213.9y
Jun 11, 2030method-of-use (U-2825)US 96690213.9y
Jun 11, 2030method-of-use (U-2825)US 96690213.9y
Jun 11, 2030method-of-use (U-2825)US 96690213.9y
Aug 7, 2029formulationUS 108210743.1y
Aug 7, 2029formulationUS 108210743.1y
Aug 7, 2029formulationUS 108210743.1y
Aug 7, 2029formulationUS 108210743.1y
Aug 7, 2029formulationUS 108210743.1y

FDA exclusivities (1)

Feb 3, 2028NPNP1.6y

apomorphine hydrochloride

indications

all catalysts(0)

News(0)

Patent cliff

patents (60)

FDA exclusivities (1)

comments(0)

Report a data issue